Obesity , a chronic condition often resistant to treatment, is commonly managed with once-weekly subcutaneous semaglutide 2.4 mg. To assess whether a higher dose could improve outcomes for those not meeting therapeutic goals, a study evaluated the efficacy and safety of semaglutide 7.2 mg in 1,407 adults with obesity. The study found that semaglutide 7.2 mg led to greater weight loss (–18.7%) than 2.4 mg (–15.6%) and placebo (–3.9%).
Participants on 7.2 mg were significantly more likely to achieve weight reductions of 5% (Odd Ratio (OD) 12.1), 10% (OD 14.5), 15% (OD 20.3), 20% (OD 27.3), and 25% (OD 127.4) compared with placebo, and more likely than those on 2.4 mg to reach 20% (OD 1.8) and 25% (OD 2.4) reductions. Waist circumference decreased by 11.7 cm, while gastrointestinal side effects were more frequent with the higher dose, but serious adverse events were similar across groups.…
